"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LUNG.
Descriptor ID |
D008175
|
MeSH Number(s) |
C04.588.894.797.520 C08.381.540 C08.785.520
|
Concept/Terms |
Lung Neoplasms- Lung Neoplasms
- Pulmonary Neoplasms
- Neoplasms, Lung
- Lung Neoplasm
- Neoplasm, Lung
- Neoplasms, Pulmonary
- Neoplasm, Pulmonary
- Pulmonary Neoplasm
Lung Cancer- Lung Cancer
- Cancer, Lung
- Cancers, Lung
- Lung Cancers
- Pulmonary Cancer
- Cancer, Pulmonary
- Cancers, Pulmonary
- Pulmonary Cancers
- Cancer of the Lung
- Cancer of Lung
|
Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".
This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 6 | 7 | 13 |
1995 | 11 | 5 | 16 |
1996 | 10 | 4 | 14 |
1997 | 9 | 0 | 9 |
1998 | 13 | 1 | 14 |
1999 | 8 | 4 | 12 |
2000 | 12 | 2 | 14 |
2001 | 12 | 5 | 17 |
2002 | 21 | 9 | 30 |
2003 | 32 | 13 | 45 |
2004 | 30 | 6 | 36 |
2005 | 35 | 11 | 46 |
2006 | 31 | 12 | 43 |
2007 | 41 | 8 | 49 |
2008 | 43 | 9 | 52 |
2009 | 36 | 4 | 40 |
2010 | 45 | 4 | 49 |
2011 | 54 | 11 | 65 |
2012 | 51 | 4 | 55 |
2013 | 59 | 5 | 64 |
2014 | 51 | 6 | 57 |
2015 | 73 | 9 | 82 |
2016 | 70 | 11 | 81 |
2017 | 65 | 3 | 68 |
2018 | 74 | 6 | 80 |
2019 | 76 | 7 | 83 |
2020 | 73 | 6 | 79 |
2021 | 85 | 3 | 88 |
2022 | 64 | 0 | 64 |
2023 | 63 | 0 | 63 |
2024 | 9 | 0 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence. Clin Cancer Res. 2024 Apr 01; 30(7):1232-1239.
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer. J Med Econ. 2024 Jan-Dec; 27(1):292-303.
-
Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia cohort consortium. Int J Cancer. 2024 Jun 15; 154(12):2090-2105.
-
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
-
ACR Lung-RADS v2022: Assessment Categories and Management Recommendations. Chest. 2024 Mar; 165(3):738-753.
-
Transfer Learning for Mortality Prediction in Non-Small Cell Lung Cancer with Low-Resolution Histopathology Slide Snapshots. Stud Health Technol Inform. 2024 Jan 25; 310:735-739.
-
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar; 199:113530.
-
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
-
"Tool-in-lesion" Accuracy of Galaxy System-A Robotic Electromagnetic Navigation BroncHoscopy With Integrated Tool-in-lesion-Tomosynthesis Technology: The MATCH Study. J Bronchology Interv Pulmonol. 2024 Jan 01; 31(1):23-29.
-
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 01; 187:107441.